Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-4975

Apixaban 2.5mg for DVT prophylaxis in cancer patients

XMLWordPrintable

    • Icon: EH/CAH eCQMs EH/CAH eCQMs
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Stephanie Battista
    • 202-503-7556
    • MedStar Health
    • Hide
      ​Thank you for your inquiry on CMS108, Venous Thromboembolism Prophylaxis. We continuously monitor FDA approved indications for medications included in the value set, e.g., apixaban. At this time, there is no approved indication to use apixaban for DVT prophylaxis in cancer. Please see FDA package insert list of approved indications https://packageinserts.bms.com/pi/pi_eliquis.pdf
      Show
      ​Thank you for your inquiry on CMS108, Venous Thromboembolism Prophylaxis. We continuously monitor FDA approved indications for medications included in the value set, e.g., apixaban. At this time, there is no approved indication to use apixaban for DVT prophylaxis in cancer. Please see FDA package insert list of approved indications https://packageinserts.bms.com/pi/pi_eliquis.pdf
    • CMS0108v10
    • CMS108v9/NQFna
    • CMS108v8/NQFna
    • Cancer patients are not meeting the numerator for DVT prophylaxis when administered Apixaban 2.5mg

      There is recent evidence that Apixaban 2.5 mg is effective for DVT Prophylaxis in cancer patients. Our Urologic Oncology group has started prescribing this for their patients. Will Apixaban 2.5mg usage for DVT prophylaxis be expanded to include other diagnoses and conditions such as cancer?

            JLeflore Mathematica EH eCQM Team
            sab104 Stephanie Battista (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: